Home / Market News / $HALO
benzinga Corporate Catalyst Impact 55/100 ● positive

TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

Oct 13, 2026, 4:38 PM UTC · Primary ticker $HALO

TD Cowen analyst Brendan Smith reiterated a 'Buy' rating on Halozyme Therapeutics and increased the price target from $105 to $130. This analyst action suggests continued confidence in the company's prospects, which could positively influence investor sentiment.

TD Cowen analyst Brendan Smith maintained a 'Buy' rating on Halozyme Therapeutics and raised the price target from $105 to $130. This indicates a strengthened positive outlook from a prominent financial institution regarding HALO's future performance. For traders, this could signal a short-term positive sentiment boost and potentially attract new investors, leading to upward price movement. Long-term implications depend on whether the company's fundamentals align with this increased valuation. The key opportunity for traders is to capitalize on potential short-term momentum, while the risk lies in the possibility that the market has already priced in this analyst upgrade or that future company performance doesn't meet these elevated expectations.

$HALO positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.